Teachers Retirement System of The State of Kentucky Has $3.42 Million Position in bluebird bio, Inc. (BLUE)
Teachers Retirement System of The State of Kentucky boosted its holdings in bluebird bio, Inc. (NASDAQ:BLUE) by 8.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,587 shares of the biotechnology company’s stock after acquiring an additional 2,477 shares during the quarter. Teachers Retirement System of The State of Kentucky owned 0.07% of bluebird bio worth $3,423,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Quantitative Investment Management LLC lifted its position in bluebird bio by 1,193.8% in the 2nd quarter. Quantitative Investment Management LLC now owns 104,800 shares of the biotechnology company’s stock valued at $11,009,000 after acquiring an additional 96,700 shares in the last quarter. State of Wisconsin Investment Board bought a new position in bluebird bio in the 2nd quarter valued at approximately $3,257,000. Winfield Associates Inc. lifted its position in bluebird bio by 6.1% in the 2nd quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock valued at $296,000 after acquiring an additional 162 shares in the last quarter. OMERS ADMINISTRATION Corp bought a new position in bluebird bio in the 2nd quarter valued at approximately $1,061,000. Finally, Alliancebernstein L.P. lifted its position in bluebird bio by 50.1% in the 1st quarter. Alliancebernstein L.P. now owns 85,860 shares of the biotechnology company’s stock valued at $7,805,000 after acquiring an additional 28,640 shares in the last quarter.
Shares of bluebird bio, Inc. (BLUE) opened at 137.35 on Friday. The stock’s market cap is $6.26 billion. The firm has a 50-day moving average price of $108.37 and a 200-day moving average price of $97.10. bluebird bio, Inc. has a 52 week low of $37.05 and a 52 week high of $143.50.
bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.66) by ($0.07). The business had revenue of $16.70 million for the quarter, compared to analyst estimates of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The company’s revenue for the quarter was up 977.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.59) earnings per share. On average, equities analysts anticipate that bluebird bio, Inc. will post ($6.84) earnings per share for the current year.
Several equities analysts recently issued reports on BLUE shares. Maxim Group raised bluebird bio from a “hold” rating to a “buy” rating and set a $100.00 price objective on the stock in a research report on Friday, June 2nd. ValuEngine raised bluebird bio from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Cantor Fitzgerald set a $37.00 price target on bluebird bio and gave the company a “sell” rating in a report on Monday, June 5th. Bank of America Corporation reissued a “hold” rating and set a $95.00 price target on shares of bluebird bio in a report on Monday, June 5th. Finally, BMO Capital Markets raised bluebird bio from a “market perform” rating to an “outperform” rating and increased their price target for the company from $61.00 to $108.00 in a report on Monday, June 5th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $107.86.
In related news, Director Mark Vachon sold 6,000 shares of the business’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $126.82, for a total transaction of $760,920.00. Following the completion of the transaction, the director now directly owns 8,000 shares in the company, valued at $1,014,560. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John Maraganore sold 18,868 shares of the business’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $131.21, for a total transaction of $2,475,670.28. Following the transaction, the director now owns 24,711 shares of the company’s stock, valued at $3,242,330.31. The disclosure for this sale can be found here. Insiders have sold 133,829 shares of company stock valued at $16,006,899 over the last 90 days. 3.90% of the stock is currently owned by insiders.
bluebird bio Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Stock Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related stocks with our FREE daily email newsletter.